If the FDA’s decision in September 2005 to ask for additional safety data on the dual PPAR agonist muraglitazar (Pargluva, from Bristol-Myers Squibb Co. and Merck & Co. Inc. [See Deal]) virtually killed development of all such compounds, the data presented less than a year later at the American Diabetes Association annual meeting has Big Pharma excited again about the potential for new classes of diabetes drugs.
Attendees at that meeting got perhaps their first clear picture of the competitive landscape emerging around inhibitors of the enzyme...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?